Your Health, We Care
In the pursuit of health and recovery, rational use of drugs is a crucial part. Patients should be fully aware of the information about the drug, including but not limited to efficacy, dosage, and contraindications, before using any drug. Be sure to follow the doctor's guidance and do not increase or decrease the dose or change the drug at will, so as not to affect the efficacy or cause adverse reactions; Be aware of drug-drug interactions and avoid self-medication.
Pralsetinib, also known as GAVRETO, is a targeted therapy medication administere···【more】
Release date：2026-01-16Recommended：128
Pralsetinib is a tyrosine kinase inhibitor administered via oral route.Which Pat···【more】
Release date：2026-01-16Recommended：75
Trabectedin (Yondelis) is a prescription medication indicated for the treatment ···【more】
Release date：2026-01-16Recommended：86
On December 1, 2020, South San Francisco, California – Genentech, a member of th···【more】
Release date：2026-01-15Recommended：104
On August 9, 2023, the U.S. Food and Drug Administration (FDA) approved pralseti···【more】
Release date：2026-01-15Recommended：86
Pralsetinib is indicated for the treatment of patients with metastatic (spread) ···【more】
Release date：2026-01-15Recommended：73
Pralsetinib is indicated for the treatment of patients with advanced or metastat···【more】
Release date：2026-01-15Recommended：113
As a novel AKT inhibitor, the drug interactions of capivasertib represent a crit···【more】
Release date：2026-01-13Recommended：134
Although capivasertib offers a new treatment option for specific cancers, its ef···【more】
Release date：2026-01-13Recommended：116
Do not take other medications unless you have discussed them with your doctor. T···【more】
Release date：2026-01-13Recommended：135
This medicine may affect your blood glucose levels. If you experience increased ···【more】
Release date：2026-01-13Recommended：134
Capivasertib (trade name: Truqap) is an oral pan-AKT inhibitor. In combination w···【more】
Release date：2026-01-13Recommended：144
